MLTX MEXC RealStocks
Own real MLTX shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-13 21:26:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
MoonLake Immunotherapeutics (MLTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $12.49, with a market capitalization of $1.10B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $9.46 to $23.29. This page covers its latest market performance, valuation, price trends and company information.
$1.10B | |
$12.86 | |
$13.36 | |
$12.38 | |
$12.87 | |
1.10M | |
1.62M | |
-- | |
$23.29 | |
$9.46 | |
-- | |
-- |
MoonLake Immunotherapeutics (MLTX) is trading at $12.50 in after-hours trading as of 2026-11-13 21:16:00, up 0.09% ($0.01) from the regular-session close of $12.49.
After-hours trading shows how investors are pricing MLTX after the regular session closes. The current after-hours price is near the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, MoonLake Immunotherapeutics (MLTX) moved from $10.80 to $12.49, representing a gain of 15.64% ($1.69).
The stock traded between $10.67 and $13.90 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 1.19 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 21.9%
MLTX is currently trading at $12.49, placing it 21.9% of the way from its 52-week low of $9.46 to its 52-week high of $23.29. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 130 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of MoonLake Immunotherapeutics (MLTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to MLTX, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between MLTX shares and USD.
MLTX Shares to USD
1.00 MLTX shares = 12.489 USD
Calculations are estimates based on the latest available price and are for reference only.